The Japanese Breast Cancer Society Clinical Practice Guidelines, 2018 edition: the tool for shared decision making between doctor and patient
- 52 Downloads
The Breast Cancer Clinical Practice Guidelines, 2018 edition, written in Japanese and organized by the Japanese Breast Cancer Society, were published in Japanese in May 2018. The process of making these guidelines, as well as the content, was largely changed and compared with previous editions. The concept of these guidelines is to act as a support tool for shared decision making between doctor and patient. The procedure of creating the guidelines referred to Minds Handbook for Clinical Practice Guideline Development 2014. This guideline, written in Japanese, consists of two booklets: (1) the epidemiology and diagnosis booklet covering screening, radiological, and pathological diagnosis and (2) the treatment booklet covering surgical therapy, radiation therapy, and systemic therapy. This review article consists of five parts, including the history of the Breast Cancer Clinical Practice Guidelines, the concept, process, content, and recommendation grade. I believe this brief summary concerning the Breast Cancer Clinical Practice Guidelines 2018 edition in English will be helpful for both Japanese and foreign investigators.
KeywordsGuideline Breast cancer Japan
We express our heartfelt gratitude to Fujimi Kawai of The Japan Medical Library Association and Prof. Masahiro Yoshida of International University of Health and Welfare, and Japan Council for Quality Health Care who provided extensive support and teach us fundamental advices. We thank Mrs. Hitomi Sasaki and Kazuyo Uno of Kanehara Publishing Co., Ltd for your special support. The Japanese Breast Cancer Society Clinical Practice Guidelines which is described in this review manuscript was made according to the fund from Japanese Breast Cancer Society.
Compliance with ethical standards
Conflict of interest
Hiroji Iwata received research funding from Chugai, Novartis, MSD, and Lilly and honoraria from Chugai, AstraZeneca, and Daiichi Sankyo and serves as an advisory board to Daiichi Sankyo, Chugai, Lilly, Kyowa Hakko Kirin, Pfizer, Novartis, and AstraZeneca. Shigehira Saji received research funding from Chugai, AstraZeneca, Eisai, Takeda, Novartis, Taiho, Nihon Kayaku, and Ono; honoraria from Chugai, AstraZeneca, Eisai, Takeda, Novartis, Taiho, Nihon Kayaku, Kyowa Kirin, Pfizer, and Daiichi-Sankyo and serves as an advisory board to Chugai, Kyowa Kirin, and Novartis. Masahiko Ikeda received research funding from Hisamitsu and honoraria from Chugai, Daiichi Sankyo, Kyowa Hakko Kirin, and Pfizer. Tatsuya Toyama received research funding from Chugai, AstraZeneca, Eisai, and Novartis and honoraria from Chugai, AstraZeneca, Eisai, Novartis, Lilly, Kyowa Kirin, Taiho, Daiichi-Sankyo, Takeda, Nihon Kayaku, and Pfizer. Rie Horii received honoraria from Chugai, Roche Diagnostics, AstraZeneca, Taiho, Takeda, Pfizer, and Eisai and serves as advisory board to Chugai. Masashi Inokuchi, Takayoshi Uematsu, and Chikako Yamauchi have no conflicts of interest.
Human participants and animals participant right statement
This article does not contain any studies with human participants or animals performed by any of the authors.